Pressemeddelelse fra Lyhne Life ApS
Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders Kronborg, as new Chief Executive Officer (CEO), effective February 1, 2023. Mr. Kronborg is a recognized industry leader with global executive experience in the pharma industry – latest as CFO/EVP and interim CEO in Leo Pharma.
“We are happy to welcome Anders as our new CEO of ResoTher Pharma. Anders has a proven track record with executive positions in publicly listed international companies. We look forward to working with Anders, who will bring substantial experience from a broad range of financing and commercial transactions, for the further development of ResoTher Pharma” said Kirsten Drejer, Chairman of the Board and continues “We want to express our gratitude and appreciation to Lone Veng, who will be vacating the CEO seat, for her leadership of ResoTher Pharma since 2017. Lone has been instrumental in the early development of the company and for bringing the lead compound RTP-026 into clinical development”.
Lone Veng, former CEO of ResoTher Pharma, added: “I joined ResoTher Pharma when the company was newly founded based on exciting research on resolution therapy from William Harvey Research Institute in London. During my leadership, we have moved RTP-026 into clinical development and are soon ready to test the drug candidate in the first studies in patients. I am happy and proud to have matured the company to the mid- clinical stage and look forward to handing over the baton to Anders, who has excellent experience to lead the company into the next stages going forward.”
Anders Kronborg, New CEO of ResoTher Pharma commented: “I am indeed impressed with what ResoTher has achieved as a small biotech company. The concept of resolution therapy with RTP-026, could potentially transform the way we treat a number of cardiovascular diseases including myocardial infarction. It will be exciting to work with the team and lead the company to further success. I also want to express my respect to Lone, who together with a very small team and the founders successfully have built ResoTher Pharma from idea to now being a biotech company with a clinical program soon ready to enter phase 2 testing in patients.”
Anders Kronborg, started his career in the Ministry of Finance in 1995 and has held executive positions as CFO and CEO for Berlingske Tidende, CFO in TV2, CFO and EVP in Metro International, COO in Kinnivik Investment AB and CFO/EVP and interim CEO in Leo Pharma. Anders has a master’s degree in Economics from University of Copenhagen.
About ResoTher Pharma A/S:
ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark, The company is focussed on developing peptide-based drugs as resolution therapy for chronic and acute inflammatory diseases. Our current focus is on developing novel treatments for cardiovascular and inflammatory disorders with a large unmet medical need.
Kontakt:
Chairwoman Kirsten Drejer tlf.: + 45 22 10 99 59
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/resother-pharma-appoints-anders-kronborg-as-chief-executive-officer?releaseId=13669711
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
